• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SPL
Click for more information
0.00% 10.5¢

STARPHARMA HOLDINGS LIMITED - Announcements

Market Cap $43.82M  ! watchlist Created with Sketch. Add to my watchlist

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The... Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
SPLStarpharma Interim Report and Half-year Financial ResultsPRICE SENSITIVE24/02/14
SPLAppendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/01/14
SPLResponse to ASX Price QueryPRICE SENSITIVE23/01/14
SPLStarpharma commences Dendrimer-Docetaxel clinical trialPRICE SENSITIVE23/01/14
SPLStarpharma to recoup additional $2 million for overseas R&DPRICE SENSITIVE14/01/14
SPLCancer Australia funding for dendrimer-based lung treatmentPRICE SENSITIVE19/12/13
SPLAppendix 4C - quarterlyPRICE SENSITIVE28/10/13
SPLStarpharma Dendrimer-Docetaxel eliminates neutropeniaPRICE SENSITIVE24/10/13
SPLReduced neurotoxicity - SPL's dendrimer enhanced oxaliplatinPRICE SENSITIVE14/10/13
SPLSPL Signs Priostar Agrochemical Partnership with GowanPRICE SENSITIVE16/09/13
SPLDendrimer-Oxaliplatin shows better anti-cancer efficacyPRICE SENSITIVE11/09/13
SPLAnnual report and full year financial resultsPRICE SENSITIVE26/08/13
SPLAppendix 4C - quarterlyPRICE SENSITIVE25/07/13
SPLARC grant for Starpharma's targeted drug deliveryPRICE SENSITIVE11/07/13
SPLSPL's dendrimer a potential viral conjunctivitis treatmentPRICE SENSITIVE13/05/13
SPLAppendix 4C - quarterlyPRICE SENSITIVE24/04/13
SPLStarpharma Granted New Drug Delivery PatentsPRICE SENSITIVE17/04/13
SPLDendrimers improve anticancer efficacy lung metastasis modelPRICE SENSITIVE04/03/13
SPLHalf Yearly Report and AccountsPRICE SENSITIVE14/02/13
SPLAppendix 4C - quarterlyPRICE SENSITIVE30/01/13
SPLSPL docetaxel superior to Taxotere across multiple cancersPRICE SENSITIVE06/12/12
SPLVivaGel phase 3 study resultsPRICE SENSITIVE28/11/12
SPLTrading HaltPRICE SENSITIVE28/11/12
SPLStarpharma to recoup $6 million cash for overseas R&DPRICE SENSITIVE22/11/12
SPLStarpharma presenting at Bell Potter LifeScience ConferencePRICE SENSITIVE01/11/12
SPLAppendix 4C - quarterlyPRICE SENSITIVE31/10/12
SPLNew formulations show further improvement in crop protectionPRICE SENSITIVE30/10/12
SPLStarpharma's docetaxel demonstrates targeted tumour deliveryPRICE SENSITIVE29/10/12
SPLVivaGel BV Phase 3 trials - recruitment completePRICE SENSITIVE18/10/12
SPLStarpharma signs cancer drug agreement with AstraZenecaPRICE SENSITIVE06/09/12
SPLAnnual Report and full year financial resultsPRICE SENSITIVE27/08/12
NUF +Starpharma and Nufarm sign crop protection agreementPRICE SENSITIVE07/08/12
SPLAppendix 4C - quarterlyPRICE SENSITIVE30/07/12
SPLReports rapid advancement of drug delivery programPRICE SENSITIVE03/07/12
SPLFull enrolment achieved for BV Phase 2 & first Phase 3 trialPRICE SENSITIVE25/06/12
SPLStarpharma's VivaGel Phase 3 trials 60% enrolledPRICE SENSITIVE04/06/12
SPLAppendix 4C - quarterlyPRICE SENSITIVE30/04/12
SPLResponse to an ASX price queryPRICE SENSITIVE24/04/12
SPLSPL Commences pivotal phase 3 VivaGel BV treatment trialsPRICE SENSITIVE22/03/12
SPLHalf Yearly Report and AccountsPRICE SENSITIVE20/02/12
SPLSPL's dendrimers improve efficacy of docetaxel in animalsPRICE SENSITIVE01/02/12
SPLAppendix 4C - quarterlyPRICE SENSITIVE30/01/12
SPLSPL receives FDA Special Protocol Assessment for BV Phase 3PRICE SENSITIVE11/01/12
SPLStarpharma's drug delivery program with Lilly advancesPRICE SENSITIVE19/12/11
SPLStarpharma secures European (EMA) agreement on BV Phase 3PRICE SENSITIVE21/11/11
SPLStarpharma completes A$32 million placement, SPP to followPRICE SENSITIVE16/11/11
SPLTrading HaltPRICE SENSITIVE14/11/11
SPLAppendix 4C - quarterlyPRICE SENSITIVE27/10/11
SPLStarpharma secures FDA agreement on BV treatment Phase 3PRICE SENSITIVE10/10/11
ACR +SandP Indices Announces September Quarterly RebalancePRICE SENSITIVE09/09/11
SPLAnnual report and full year financial resultsPRICE SENSITIVE29/08/11
SPLGSK awarded funds for dermal treatment with SPL's dendrimersPRICE SENSITIVE22/08/11
ANN +SPL terminates Reckitt agreement and signs with AnsellPRICE SENSITIVE17/08/11
SPLSPL Commences VivaGel Bacterial Vaginosis Prevention StudyPRICE SENSITIVE15/08/11
SPLAppendix 4C - quarterlyPRICE SENSITIVE28/07/11
SPLStarpharma advances agrochemical programPRICE SENSITIVE12/07/11
SPLAdvances leading cancer therapeutic in drug delivery programPRICE SENSITIVE29/06/11
SPLVivaGel Demonstrates Efficacy in Bacterial VaginosisPRICE SENSITIVE23/05/11
SPLVivaGel Coated Condom Licence Agreement with Okamoto JapanPRICE SENSITIVE10/05/11
SPLAppendix 4C - quarterlyPRICE SENSITIVE27/04/11
SPLCompletes enrolment for Phase 2 study of VivaGel for BVPRICE SENSITIVE23/03/11
SPLSPL to expand agricultural program through $250,000 fundingPRICE SENSITIVE03/03/11
SPLHalf Yearly Report and AccountsPRICE SENSITIVE21/02/11
SPLResponse to ASX QueryPRICE SENSITIVE09/02/11
SPLAppendix 4C - quarterlyPRICE SENSITIVE31/01/11
SPLResponse to an ASX Price QueryPRICE SENSITIVE18/11/10
SPLStarpharma's partner SSL acquired by Reckitt BenckiserPRICE SENSITIVE04/11/10
SPLAppendix 4C - quarterlyPRICE SENSITIVE25/10/10
SPLStarpharma Expands Lilly PartnershipPRICE SENSITIVE30/09/10
SPLAnnual Report and full year financial resultsPRICE SENSITIVE25/08/10
SPLVivaGel condom patent grant extends coveragePRICE SENSITIVE18/08/10
SPLStarpharma announces Phase 2 BV study of VivaGelPRICE SENSITIVE16/08/10
SPLAppendix 4C - quarterlyPRICE SENSITIVE27/07/10
SPLStarpharma's Bacterial Vaginosis Study gets FDA ClearancePRICE SENSITIVE15/07/10
SPLSPL and Monash University collaboration receives ARC grantPRICE SENSITIVE29/06/10
SPLAppendix 4C - quarterlyPRICE SENSITIVE27/04/10
SPLSuccessful completion of VivaGel study sexually active womenPRICE SENSITIVE12/03/10
SPLHalf Yearly Report and AccountsPRICE SENSITIVE18/02/10
SPLStarpharma and Lilly Sign New Drug Delivery CollaborationPRICE SENSITIVE01/02/10
SPLAppendix 4C - quarterlyPRICE SENSITIVE29/01/10
SPLStarpharma announces $15.6 million capital raisingPRICE SENSITIVE18/11/09
SPLReinstatement to Official QuotationPRICE SENSITIVE18/11/09
SPLSuspension from Official QuotationPRICE SENSITIVE16/11/09
SPLTrading HaltPRICE SENSITIVE12/11/09
SPLStarpharma signs agrochemicals dealPRICE SENSITIVE05/11/09
SPLAppendix 4C - quarterlyPRICE SENSITIVE23/10/09
SPLUS Patent Grant Extends VivaGel Coverage to 2024PRICE SENSITIVE22/09/09
SPLPreliminary Final ReportPRICE SENSITIVE24/08/09
SPLInterim Financial Results - Material ImprovementPRICE SENSITIVE04/08/09
SPLVivaGel - Anti-HIV and Herpes Activity following human adminPRICE SENSITIVE03/08/09
SPLAppendix 4C - quarterlyPRICE SENSITIVE27/07/09
SPLCompletes $7.1m capital raisingPRICE SENSITIVE21/05/09
SPLElanco deal triggers Starpharma SPP extensionPRICE SENSITIVE11/05/09
SPLStarpharma and Elanco sign agreementPRICE SENSITIVE11/05/09
SPLAppendix 4C - quarterlyPRICE SENSITIVE07/04/09
SPLRaises additional capital via institutional placementPRICE SENSITIVE07/04/09
SPLTrading HaltPRICE SENSITIVE03/04/09
SPLCompletes patient testing in retention of activity studyPRICE SENSITIVE19/03/09
SPLHalf Yearly Report and AccountsPRICE SENSITIVE19/02/09
SPLTopical Microbicide Field Boost With Efficacy ResultPRICE SENSITIVE10/02/09
SPLStarpharma Interim Report and Half-year Financial Results
24/02/14PRICE SENSITIVE
SPLAppendix 4C - Quarterly Cashflow Report
30/01/14PRICE SENSITIVE
SPLResponse to ASX Price Query
23/01/14PRICE SENSITIVE
SPLStarpharma commences Dendrimer-Docetaxel clinical trial
23/01/14PRICE SENSITIVE
SPLStarpharma to recoup additional $2 million for overseas R&D
14/01/14PRICE SENSITIVE
SPLCancer Australia funding for dendrimer-based lung treatment
19/12/13PRICE SENSITIVE
SPLAppendix 4C - quarterly
28/10/13PRICE SENSITIVE
SPLStarpharma Dendrimer-Docetaxel eliminates neutropenia
24/10/13PRICE SENSITIVE
SPLReduced neurotoxicity - SPL's dendrimer enhanced oxaliplatin
14/10/13PRICE SENSITIVE
SPLSPL Signs Priostar Agrochemical Partnership with Gowan
16/09/13PRICE SENSITIVE
SPLDendrimer-Oxaliplatin shows better anti-cancer efficacy
11/09/13PRICE SENSITIVE
SPLAnnual report and full year financial results
26/08/13PRICE SENSITIVE
SPLAppendix 4C - quarterly
25/07/13PRICE SENSITIVE
SPLARC grant for Starpharma's targeted drug delivery
11/07/13PRICE SENSITIVE
SPLSPL's dendrimer a potential viral conjunctivitis treatment
13/05/13PRICE SENSITIVE
SPLAppendix 4C - quarterly
24/04/13PRICE SENSITIVE
SPLStarpharma Granted New Drug Delivery Patents
17/04/13PRICE SENSITIVE
SPLDendrimers improve anticancer efficacy lung metastasis model
04/03/13PRICE SENSITIVE
SPLHalf Yearly Report and Accounts
14/02/13PRICE SENSITIVE
SPLAppendix 4C - quarterly
30/01/13PRICE SENSITIVE
SPLSPL docetaxel superior to Taxotere across multiple cancers
06/12/12PRICE SENSITIVE
SPLVivaGel phase 3 study results
28/11/12PRICE SENSITIVE
SPLTrading Halt
28/11/12PRICE SENSITIVE
SPLStarpharma to recoup $6 million cash for overseas R&D
22/11/12PRICE SENSITIVE
SPLStarpharma presenting at Bell Potter LifeScience Conference
01/11/12PRICE SENSITIVE
SPLAppendix 4C - quarterly
31/10/12PRICE SENSITIVE
SPLNew formulations show further improvement in crop protection
30/10/12PRICE SENSITIVE
SPLStarpharma's docetaxel demonstrates targeted tumour delivery
29/10/12PRICE SENSITIVE
SPLVivaGel BV Phase 3 trials - recruitment complete
18/10/12PRICE SENSITIVE
SPLStarpharma signs cancer drug agreement with AstraZeneca
06/09/12PRICE SENSITIVE
SPLAnnual Report and full year financial results
27/08/12PRICE SENSITIVE
NUF +Starpharma and Nufarm sign crop protection agreement
07/08/12PRICE SENSITIVE
SPLAppendix 4C - quarterly
30/07/12PRICE SENSITIVE
SPLReports rapid advancement of drug delivery program
03/07/12PRICE SENSITIVE
SPLFull enrolment achieved for BV Phase 2 & first Phase 3 trial
25/06/12PRICE SENSITIVE
SPLStarpharma's VivaGel Phase 3 trials 60% enrolled
04/06/12PRICE SENSITIVE
SPLAppendix 4C - quarterly
30/04/12PRICE SENSITIVE
SPLResponse to an ASX price query
24/04/12PRICE SENSITIVE
SPLSPL Commences pivotal phase 3 VivaGel BV treatment trials
22/03/12PRICE SENSITIVE
SPLHalf Yearly Report and Accounts
20/02/12PRICE SENSITIVE
SPLSPL's dendrimers improve efficacy of docetaxel in animals
01/02/12PRICE SENSITIVE
SPLAppendix 4C - quarterly
30/01/12PRICE SENSITIVE
SPLSPL receives FDA Special Protocol Assessment for BV Phase 3
11/01/12PRICE SENSITIVE
SPLStarpharma's drug delivery program with Lilly advances
19/12/11PRICE SENSITIVE
SPLStarpharma secures European (EMA) agreement on BV Phase 3
21/11/11PRICE SENSITIVE
SPLStarpharma completes A$32 million placement, SPP to follow
16/11/11PRICE SENSITIVE
SPLTrading Halt
14/11/11PRICE SENSITIVE
SPLAppendix 4C - quarterly
27/10/11PRICE SENSITIVE
SPLStarpharma secures FDA agreement on BV treatment Phase 3
10/10/11PRICE SENSITIVE
ACR +SandP Indices Announces September Quarterly Rebalance
09/09/11PRICE SENSITIVE
SPLAnnual report and full year financial results
29/08/11PRICE SENSITIVE
SPLGSK awarded funds for dermal treatment with SPL's dendrimers
22/08/11PRICE SENSITIVE
ANN +SPL terminates Reckitt agreement and signs with Ansell
17/08/11PRICE SENSITIVE
SPLSPL Commences VivaGel Bacterial Vaginosis Prevention Study
15/08/11PRICE SENSITIVE
SPLAppendix 4C - quarterly
28/07/11PRICE SENSITIVE
SPLStarpharma advances agrochemical program
12/07/11PRICE SENSITIVE
SPLAdvances leading cancer therapeutic in drug delivery program
29/06/11PRICE SENSITIVE
SPLVivaGel Demonstrates Efficacy in Bacterial Vaginosis
23/05/11PRICE SENSITIVE
SPLVivaGel Coated Condom Licence Agreement with Okamoto Japan
10/05/11PRICE SENSITIVE
SPLAppendix 4C - quarterly
27/04/11PRICE SENSITIVE
SPLCompletes enrolment for Phase 2 study of VivaGel for BV
23/03/11PRICE SENSITIVE
SPLSPL to expand agricultural program through $250,000 funding
03/03/11PRICE SENSITIVE
SPLHalf Yearly Report and Accounts
21/02/11PRICE SENSITIVE
SPLResponse to ASX Query
09/02/11PRICE SENSITIVE
SPLAppendix 4C - quarterly
31/01/11PRICE SENSITIVE
SPLResponse to an ASX Price Query
18/11/10PRICE SENSITIVE
SPLStarpharma's partner SSL acquired by Reckitt Benckiser
04/11/10PRICE SENSITIVE
SPLAppendix 4C - quarterly
25/10/10PRICE SENSITIVE
SPLStarpharma Expands Lilly Partnership
30/09/10PRICE SENSITIVE
SPLAnnual Report and full year financial results
25/08/10PRICE SENSITIVE
SPLVivaGel condom patent grant extends coverage
18/08/10PRICE SENSITIVE
SPLStarpharma announces Phase 2 BV study of VivaGel
16/08/10PRICE SENSITIVE
SPLAppendix 4C - quarterly
27/07/10PRICE SENSITIVE
SPLStarpharma's Bacterial Vaginosis Study gets FDA Clearance
15/07/10PRICE SENSITIVE
SPLSPL and Monash University collaboration receives ARC grant
29/06/10PRICE SENSITIVE
SPLAppendix 4C - quarterly
27/04/10PRICE SENSITIVE
SPLSuccessful completion of VivaGel study sexually active women
12/03/10PRICE SENSITIVE
SPLHalf Yearly Report and Accounts
18/02/10PRICE SENSITIVE
SPLStarpharma and Lilly Sign New Drug Delivery Collaboration
01/02/10PRICE SENSITIVE
SPLAppendix 4C - quarterly
29/01/10PRICE SENSITIVE
SPLStarpharma announces $15.6 million capital raising
18/11/09PRICE SENSITIVE
SPLReinstatement to Official Quotation
18/11/09PRICE SENSITIVE
SPLSuspension from Official Quotation
16/11/09PRICE SENSITIVE
SPLTrading Halt
12/11/09PRICE SENSITIVE
SPLStarpharma signs agrochemicals deal
05/11/09PRICE SENSITIVE
SPLAppendix 4C - quarterly
23/10/09PRICE SENSITIVE
SPLUS Patent Grant Extends VivaGel Coverage to 2024
22/09/09PRICE SENSITIVE
SPLPreliminary Final Report
24/08/09PRICE SENSITIVE
SPLInterim Financial Results - Material Improvement
04/08/09PRICE SENSITIVE
SPLVivaGel - Anti-HIV and Herpes Activity following human admin
03/08/09PRICE SENSITIVE
SPLAppendix 4C - quarterly
27/07/09PRICE SENSITIVE
SPLCompletes $7.1m capital raising
21/05/09PRICE SENSITIVE
SPLElanco deal triggers Starpharma SPP extension
11/05/09PRICE SENSITIVE
SPLStarpharma and Elanco sign agreement
11/05/09PRICE SENSITIVE
SPLAppendix 4C - quarterly
07/04/09PRICE SENSITIVE
SPLRaises additional capital via institutional placement
07/04/09PRICE SENSITIVE
SPLTrading Halt
03/04/09PRICE SENSITIVE
SPLCompletes patient testing in retention of activity study
19/03/09PRICE SENSITIVE
SPLHalf Yearly Report and Accounts
19/02/09PRICE SENSITIVE
SPLTopical Microbicide Field Boost With Efficacy Result
10/02/09PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $43.82M
Open High Low Value Volume
10.5¢ 11.5¢ 10.0¢ $110.6K 1.006M

Buyers (Bids)

No. Vol. Price($)
1 83046 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 30000 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
10.5¢ 		  Change
0.000 ( 5.00 %)
Open High Low Volume
10.3¢ 11.5¢ 10.3¢ 347942
Last updated 15.58pm 15/11/2024 ?
SPL (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks Copper prices slump; Trump Wall Street rally fades; US health stocks dip on RFK appointment – and much more.
CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch CuFe Ltd (ASX:CUF) has decided not to wait around for Northern Star's Crossroads mine to get up and running, selling its $4M royalty right.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.